HR Execs on the Move

CancerLinQ

www.cancerlinq.org

 
CancerLinQ, a subsidiary of ASCO, is a mission-driven, non-profit health technology company focused on improving quality of care, advancing biomedical research, and improving health outcomes for all patients with cancer. Backed by ASCO, CancerLinQ`s products and services reflect a deep understanding of the needs of oncologists, cancer centers, and researchers. We are bilingual by design: fluent in both the language of oncology and technology. As a trusted partner to over 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cancerlinq.org
  • 2318 Mill Road Suite 600
    Alexandria, VA USA 22314
  • Phone: 703.299.0158

Executives

Name Title Contact Details

Similar Companies

Calibrate

Calibrate is a modern, medical metabolic health business changing the way the world treats weight.

The Health and Rejuvenation Center

The Health and Rejuvenation Center is a Palm Beach Gardens, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurostream Technologies

Neurostream Technologies is a Saint-Augustin-De-Desmaures, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

TDC Medical Inc

TDC Medical Inc is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.